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Purpose: To prepare oral sustained release matrix tablets of a highly water soluble drug, tramadol 
hydrochloride, and to evaluate the effect of concentration of the hydrophobic polymer content and 
method of preparation on drug release. 
Methods: The tablets were a mixture of both tramadol hydrochloride and glyceryl palmitostearate (GP) 
prepared by melt granulation (MG1, MG2, MG3 and MG4 in ratios 1:1, 1:2, 1:3 and 1:4, respectively) or 
by direct compression (DC, 1:2 ratio). The hardness of the tablets was measured. Drug/GP interaction 
was determined by FT-IR spectroscopy while drug release from the matrix tablets was studied using 
USP ІІ dissolution apparatus. The release data were subjected to different models in order to evaluate 
their release kinetics and mechanisms.  
Results:  The hardness of the tablets was in the range of 5.30 ± 0.36 - 6.50 ± 0.10 kg/cm
2
. FT-IR 
spectra showed that there was no clear interaction between the drug and the glyceride. Of the 
formulations (MG1 to MG4) prepared by melt granulation, MG4 showed the most suitable sustained 
release, 58.4 ± 1.1 % in 12 h (p < 0.05). Drug release (98.2 ± 0.2 % in 8 h) was highest for DC which 
was prepared by direct compression. Also, drug release mechanism for the formulations was by Fickian 
diffusion.  
Conclusion: Glyceryl palmitostearate is a suitable matrix-forming agent to sustain the release of a 
water-soluble drug such as tramadol hydrochloride. Melt granulation was a better technique for 
formulating the product than direct compression.        
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INTRODUCTION 
 
A sustained-release dosage form is defined 
as “any drug or dosage form modification that 
prolongs the therapeutic activity of the drug” 
[1]. The primary objectives of sustained drug 
delivery are to ensure safety and 
enhancement of efficacy of drug with 
improved patient compliance. This delivery 
system is increasingly being used in the 
treatment of acute and chronic diseases as 
they maintain the concentration of drug in 
plasma above the minimum effective 
concentration and below the minimum toxic 
level for an extended period of time. Thus, 
sustained drug delivery results in optimum 
drug therapy with reduced frequency of 
dosing and side effects [2].  
 
Glycerides are a family of excipients which 
have generated considerable interest in the 
preparation of oral dosage forms. Some 
glycerides such as Precirol ATO 5 (glyceryl 
palmitostearate) can be used for the 
preparation of sustained release dosage 
forms
 
[3]. The esterification of glycerol by 
long chain fatty acid gives them a 
pronounced hydrophobic character with a low 
HLB value of 2 [4]. Several techniques 
including melt granulation [5], melt 
pelletization [6], hot melt extrusion [7] and hot 
melt coating [8] have been used to obtain 
sustained release dosage forms from 
glycerides-based formulations. Melt 
granulation is a solvent-free process which 
involves the use of a substance that melts at 
a relatively low temperature. This substance 
can be added in the molten form over the 
substrate or in the solid form, which is then 
heated above its melting point. The 
substance acts as a liquid binding agent, and 
the technique does not require the use of 
organic solvents. Moreover, in melt 
granulation drying is not necessary and thus, 
the process is less consuming in terms of 
time and energy compared to other methods 
[9]. Sustained release matrix tablets have 
been produced with Precirol ATO 5 by 
various methods including melt granulation 
[10], hot melt extrusion [11] and melt 
pelletization [6]. 
 
Tramadol Hydrochloride (TH), a synthetic 
opioid of the aminocyclohexanol group, is a 
centrally acting analgesic. The melting point 
of GP and tramadol hydrochloride (TH) is 52 
– 55 and 180 – 184 °C, respectively. 
Therefore, TH is a thermally stable drug and 
melt granulation technique should not affect 
the thermal stability of the drug.  It was 
approved by United States Food and Drug 
Administration (US FDA) in 1995 and has 
been proved to be effective in both 
experimental and clinical pain without 
causing serious cardiovascular or respiratory 
side effects [12]. It has a plasma elimination 
half-life of 4 - 6 h with a usual dosage 
regimen of 50-100 mg every 4 - 6 h. 
Therefore, to reduce frequency of 
administration and improve patient 
compliance, a sustained release dosage 
formulation of tramadol is desirable. The drug 
is associated with certain side effects, such 
as abdominal pain and anorexia, and may 
also induce psychic and physical 
dependence. Therefore, a properly designed 
sustained release dosage form of the drug 
should also minimize fluctuation in blood 
concentration, reduced risk of side effects 
and show uniform pharmacological response 
[13].  
 
Hydrophobic matrix tablets have previously 
been produced to yield sustained tramadol 
formulations using hydrogenated castor oil 
and ethyl cellulose[14],
 
and glyceryl behenate 
[15]. Various monoolein-water systems have 
been tested in this regard [16] while the drug 
has also been complexed with a sulfonic acid 
cation-exhange resin in a microencapsulation 
process using a spray-drying method [17]. 
The objective of the present study was to 
prepare oral sustained release matrix tablet 
of a highly water soluble drug by melt 
granulation using glyceryl palmitostearate, 
and to evaluate the effect of the 
concentration of the glyceride on the release 
of the drug. Such a sustained release 
formulation, if achieved, would be 
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substantially more affordable than those 




Materials   
 
Tramadol hydrochloride was a gift from Neon 
Laboratories Ltd, Mumbai, India while 
glyceryl palmitostearate (Precirol ATO 5) was 
obtained free of charge from Gattefosse 
Corp, France.  Concentrated hydrochloric 
acid, sodium hydroxide and potassium 
dihydrogen phosphate were also obtained 
free of charge from Fine Chemicals Ltd, 
Mumbai, India.                                                                       
 
Preparation of tramadol hydrochloride 
matrix tablets   
 
Melt granulation method   
 
The matrix tablets were composed as shown 
in Table 1. Glyceryl palmitostearate (GP) 
melted in a porcelain dish over a water bath 
maintained at 75 °C for 3 min and tramadol 
hydrochloride (TH) was gradually added with 
continuous stirring until uniformly mixed. The 
molten mixture was allowed to cool and 
solidify at room temperature crushed in a 
mortar and passed through a 1190 µm 
aperture sieve. The granules were 
compressed into 8 mm diameter flat–faced 
tablets using a press (single punch, 
semiautomatic, model 999, Shimadzu 
Corporation, Kyoto, Japan) at a force of 1 
ton.  
 









MG1 TH: GP (1:1) 200 
MG2 TH: GP (1:2) 300 
MG3 TH: GP (1:3) 400 
MG4 TH: GP (1:4) 500 
DC TH: GP (1:2) 300 
Note: TH =tramadol hydrochloride; GP = glyceryl 
palmitostearate 
Direct compression method  
 
The drug (TH) and the glyceride (GP) were 
mixed together (see Table 1) in a mortar for 
10 min, and compressed into flat-faced 
tablets by direct compression.  
 
Evaluation of drug - glyceride interaction  
 
The pure drug, wax and the matrix tablet 
formulation were subjected to IR 
spectroscopy using FT-IR spectrophotometer 
(IRAffinity-1, Shimadzu). Their spectra were 
obtained over the wave number range of 
4000 – 400 cm
-1
.               
 
Determination of drug content of granules 
 
Drug content was determined by dispersing a 
quantity of the pre-compression granules, 
equivalent to100 mg of tramadol 
hydrochloride, in 70 ml of distilled water. It 
was shaken for 15 min, diluted to 100 ml with 
distilled water and then filtered through 
Whatman filter paper no. 41. One ml of this 
solution was transferred to a 10 ml volumetric 
flask, the final volume made 10 ml, and the 
absorbance of the resulting solution 
measured using a UV spectrophotometer (UV 
– 1800, Shimadzu corporation, Kyoto, Japan) 
at 271 nm. Drug content was determined 
from the absorbance data.  
   
Evaluation of in vitro drug release  
 
In vitro dissolution assessment of the tablets 
was carried out in a USP ІІ dissolution 
apparatus (Electrolab, TDT-08L). Nine 
hundred millilitres of 0.1 M HCl was used as 
the dissolution medium for 2 h and then 
replaced with phosphate buffer (pH 6.8) as 
the dissolution medium for another 8 h. The 
medium change was effected by adding 4.32 
g of sodium hydroxide and 6.08 g of 
potassium dihydrogen phosphate dissolved in 
5 ml water to the acid [18]. Test temperature 
was 37±0.5
o
 C while paddle rotation speed 
was kept at 100 rpm. At predetermined time 
intervals, 5 ml samples were withdrawn over 
a period of 12 h, filtered, suitably diluted and 
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assayed at 271 nm spectrophotometrically 
(Shimadzu 1800). Sink condition was 
maintained by replenishing the dissolution 
medium with 5 ml fresh dissolution fluid on 
each occasion. All tests were carried out in 
triplicate. The regression equation of the 
calibration curve was: y = 0.0053x + 0.0133 
(r
2
=0.9996, n=9) (p < 0.05). 
 
Drug release kinetics  
 
To determine the mechanism of drug release 
from the formulations, the data were 
subjected to zero-order (Eq 1), first order (Eq 
2) and Highuchi (Eq 3) release kinetics 
[19,20] 
 
Mt    = M0 + k0t ….………………………… (1) 
 
In Mt    = In M0 + k1t ………….………….. (2) 
 
Mt    = M0 + kHt
1/2
 ………………….……... (3) 
 
where Mt is the cumulative amount of drug 
released at any time, t, and M0 is the dose of 
the drug incorporated in the delivery system. 
k0, k1 and kH are rate constants for zero-order, 
first order and Higuchi models, respectively. 
The dissolution data were also fitted 
according to the well-known exponential 
equation of Peppas [21], as in Eq 4, which is 
often used to describe drug release 




  ……………….………………..  (4) 
 
where, Mt/Mα is the fraction of drug released 
at time, t, k is the kinetic constant, and n is 
the diffusional exponent for drug release. The 
diffusional exponent, n, is dependent on the 
geometry of the device as well as the 
physical mechanism of release. Zero order 
release describes a release rate independent 
of drug concentration while the Higuchi 
square root kinetic model describes a time-
dependent release process. The value of n 
indicates the drug release mechanism; if 0.1 
< n < 0.5, Fickian diffusion is indicated while 
0.5 < n < 1 indicates non-Fickian diffusion. 
 
 
Statistical analysis    
 
Statistical analysis was performed using 
GraphPad InStat 3 and GraphPad Prism 5 
software. All tests were run 3 times (n = 3) 
except the pre-compression parameter. 
Experimental results were expressed as 
mean ± SD, and Student’s t-test and one-way 
analysis of variance (ANOVA) were applied 
to determine significant difference. 
Differences were considered to be 




FT-IR Spectroscopy                                                        
 
The infrared spectra of the drug, glyceride 
and tablet formulation are shown in Fig 1. 
The major IR peaks observed in the spectra 
for tablet formulation were 1737 (C=O 
stretching, carbonyl group), 1625 (C=C 
stretching) which are characteristic of glyceryl 
palmitostearate, and also 2780 (C-H 
stretching), 3392 (N-H stretching vibration, 
tertiary amine), and 1295 (C-N stretching 
vibration) which are characteristic of tramadol 
hydrochloride. When this is compared to the 
spectra of the drug and glyceride, it would 
appear that there was no obvious interaction 




Fig 1: FTIR spectra of tramadol 
hydrochloride (A), glyceryl palmitostearate 
(B) and tablet formulation containing both the 
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Table 2: In vitro release kinetics of tramadol hydrochloride matrix tablets 
 
















)±SD (n)     (R
2
)±SD 
MG1 93.34±0.89 0.996±0.005 0.924±0.022 0.977±0.004 0.3271 0.949±0.006 
MG2 81.58±1.29 0.996±0.003 0.963±0.001 0.968±0.005 0.2929 0.934±0.012 
MG3 69.66±1.02 0.994±0.006 0.987±0.003 0.975±0.007 0.2610 0.938±0.014 
MG4 58.36±1.09 0.993±0.004 0.995±0.004 0.981±0.007 0.2110 0.941±0.016 
DC 98.18±0.20 0.997±0.006 0.854±0.009 0.984±0.007 0.3868 0.970±0.009 
 
 SD=Standard deviation (n=3). The difference between batch series ‘MG’ and ‘DC’ was significant (p < 0.05). 
 
In vitro drug release 
 
The drug release data are shown in Table 2. 
Expectedly, drug release from the tablets 
prepared by melt granulation was 93.3 ± 0.9, 
81.6 ± 1.3, 69.7 ± 1.0 and 58.4 ± 1.1 % after 
12 h for formulations MG1, MG2, MG3 and 
MG4, respectively, thus indicating that drug 
release fell as the glyceride content of the 
tablets increased. The difference in release 
rate between the batches was statistically 
significant (p < 0.05). Furthermore, 
comparison of the two methods of formulation 
used indicate that cumulative release from 
the tablets prepared by direct compression 
(DC, 98.2 %) was significantly higher (p < 
0.05) than from the equivalent formulation 
made by melt granulation (MG2, 81.6 %) 
 
Drug release kinetics  
 
Table 2 shows that the best-fit release kinetic 
data with the highest values of regression 
coefficient (R
2
) were shown by zero order and 
Higuchi models. The values of n were in the 
range of 0.2110 to 0.3868 (i.e., less than 0.5) 
indicating Fickian release (diffusion-
controlled). R
2
 data indicate that Higuchi and 
Peppas models also suitably described the 







Effect of concentration of the glyceride 
matrix on drug release     
 
During preliminary studies (not reported 
here), it was observed that at low 
concentrations of the glyceride, the matrices 
of the tablets readily disintegrated during 
dissolution test. This was not, however, the 
case when the content of the matrix former 
was increased, thus indicating that a 
minimum of level of the glyceride is required 
to form a proper matrix that would not readily 
disintegrate. This study revealed that as the 
concentration of lipophilic matrix material 
(i.e., the glyceride) increased, drug release 
from matrices of the met-granulated tablets 
decreased (see Fig 2). This may be due to 
slower penetration of the dissolution medium 
into the waxy matrices. Formulation MG4 
(TH:GP ratio, 1:4) which exhibited the highest 
drug release retardation, also had the highest 
matrix concentration. As stated earlier, based 
on kinetic analysis of release data, tramadol 
hydrochloride release occurred by a non-
Fickian diffusion mechanism. The initial drug 
release (i.e., in the 1
st
 hour) of 42.9, 40.0, 
37.4 and 35.5 % for MG1, MG2, MG3 and 
MG4, respectively, may be attributed to 
‘burst’ release of the drug on the tablet 
surface. Reza et al [22], has stated that the 
drug particles present on the surface of a 
matrix system were initially released into the 
surrounding media generating many pores 
and cracks which facilitate further release of 
drug and also formation of channels within 
the matrix in the case of a water soluble drug.  
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Effect of method of tablet preparation on 
drug release   
 
Fig 3 compares the release profiles of tablets 
(TH:GP ratio, 1:2) prepared by melt-
granulation and direct compression methods, 
respectively. Both cumulative drug release 
and drug release rates were higher for the 
matrix tablets made by direct compression of 
physical mixtures than for the tablets 
obtained by the compression of granules 
made by melt granulation. This can be 
attributed to the formation of a more uniform 
and, therefore, more effective coating of the 
glyceride matrix around the drug particles in 
the tablets prepared by melt granulation 
technique than in those made by direct 
compression. Thus the tablets made by the 
former technique are likely to show greater 
integrity. Consequently, while the probable 
mechanism of drug release from the direct 
compressed-matrix tablets is erosion control, 
drug release from melt granulated tablets 
would likely be diffusion-controlled as 
confirmed by the kinetic data in Table 2. 












pH 1.2, 100 rpm 




















Fig 2: Effect of different concentration of 
Precirol ATO 5 on in vitro release of 
formulation MG1 (●), MG2 (■), MG3 (▲) and 







The study showed that glyceryl 
palmitostearate (Precirol ATO 5) is an 
appropriate waxy matrix former for sustained 
release of a water-soluble drug such as 
tramadol hydrochloride. In this regard, matrix 
tablets prepared by melt granulation 
technique were far superior to those prepared 
by direct compression of the physical mixture. 
Drug release was diffusion-controlled in the 
formulations obtained by melt granulation. 
Furthermore, Higuchi and zero order release 
kinetics were achieved, thus holding out 
prospects for a low-cost oral solid dosage 
form of tramadol hydrochloride with 
prolonged drug release characteristics. 
 












pH 1.2, 100 rpm 


















Fig 3: Release profiles of sustained release 
matrix tablet made by direct compression 
(DC ▼), and melt granulation (MG ■) in the 
ratio of 1:2                            
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